Content
Executive summary
Notes and Definitions
Data sources
Accounts
Novel agents in late stage clinical development
Exchange rates
Definitions of terms
Chapter 1: Astra Zeneca Plc (Uk)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Gastrointestinal
Cardiovascular
Oncology
Respiratory
Other major products
Commercial collaborations
Research & development
Corporate and financial data
Chapter 2: Aventis Sa (France)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Cardiovascular
Anti-infectives
Antibiotics
Vaccines
Anti-allergics and respiratory
Therapeutic proteins
Oncology
CNS agents
Diabetes
Other products
Commercial collaborations
Research & development
Corporate and financial data
Chapter 3: Basf Ag (Germany)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Cardiovascular
Thyroid insufficiency
Pain/inflammation
CNS products
Anti-obesity
Commercial collaborations
Research & development
Corporate and financial data
Chapter 4: Bayer Group (Germany)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Anti-infectives
Cardiovasculars
Consumer Care
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
Chapter 5: Boehringer Ingelheim Gmbh (Germany)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Respiratory products
Cardiovasculars
Self-medication
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
Chapter 6: Glaxo Wellcome & Smithkline Beecham
Chapter 7: Glaxo Wellcome (Uk)
Corporate structure and geographic breakdown
Human pharmaceuticals
Respiratory
Antivirals
Central nervous system
Antibiotics
Gastrointestinal
Oncology
Commercial collaborations
Research & development
Corporate and financial data
Chapter 8: Smithkline Beecham Plc (Uk)
Corporate structure and geographic breakdown
Human pharmaceuticals
Anti-infectives
Neurosciences
Vaccines
Other major brands
Commercial collaborations
Research & development
Corporate and financial data
Chapter 9: Novartis Ag (Switzerland)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Arthritis
Cardiovascular
Central nervous system
Oncology
Ophthalmology
Osteoporosis
Respiratory
Transplantation
Other major products
Over-the-counter medicines
Generics
Commercial collaborations
Research & development
Corporate and financial data
Chapter 10: Roche Group (Switzerland)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Oncology
Virology
Central nervous system
Infectious disease (antibiotics)
Immunology
Metabolic and bone disorders
Cardiovascular
Dermatology
Consumer health
Commercial collaborations
Research & development
Corporate and financial data
Chapter 11: Sanofi-Synthélabo (France)
Corporate structure and geographic breakdown
Human pharmaceuticals
Cardiovasculars
CNS agents
Other products
Commercial collaborations
Research & development
Corporate and financial data
Chapter 12: Schering Ag (Germany)
Corporate structure
Geographic breakdown
Human pharmaceuticals
Fertility control and hormone therapy
CNS
Oncology
Cardiovascular
Dermatology
Commercial collaborations
Research & development
Corporate and financial data
List Of Tables
Table 1: Sales performance (1999 data)
Table 2: Domestic sales as % of total (1999)
Table 3: North American sales as % of total (1999)
Table 4: Pharmaceutical R&D expenditure (1999 data)
Table 5: Financial efficiency
Astra Zeneca Plc (Uk)
Table 1.1: Business segment analysis (year end 31 December)
Table 1.2: Geographical sales analysis (ongoing operations)
Table 1.3: Therapy area sales analysis
Table 1.4: Human pharmaceuticals - major product performance (1999)
Table 1.5: Major commercial agreements
Table 1.6: Novel agents in late stage clinical development
Table 1.7: Financial data
Aventis Sa (France)
Table 2.1: Business segment analysis (year end 31 December)
Table 2.2: Geographical sales analysis - pharmaceuticals and CropScience
Table 2.3: Human pharmaceuticals - major product performance (1999)
Table 2.4: Major commercial agreements
Table 2.5: Novel agents in late stage clinical development
Table 2.6: Financial data
Basf Ag (Germany)
Table 3.1: Business segment analysis (year end 31 December)
Table 3.2: Geographical sales analysis
Table 3.3: Major therapy classes
Table 3.4: Human pharmaceuticals - major product performance (1999)
Table 3.5: Major commercial agreements
Table 3.6: Novel agents in late stage clinical development
Table 3.7: Financial data
Bayer Group (Germany)
Table 4.1: Business segment analysis (year end 31 December)
Table 4.2: Geographical sales distribution
Table 4.3: Human pharmaceuticals - major product performance (1999)
Table 4.4: Major commercial agreements
Table 4.5: Financial data
Boehringer Ingelheim Gmbh (Germany)
Table 5.1: Business segment analysis (year end 31 December)
Table 5.2: Geographical sales distribution
Table 5.3: Human pharmaceuticals - major product performance (1999)
Table 5.4: Major commercial agreements
Table 5.5: Novel agents in late stage clinical development
Table 5.6: Financial data
Glaxo Wellcome & Smithkline Beecham
Table 6.1: Business segment analysis (pro forma data year end 31 December)
Table 6.2: Human pharmaceuticals - major product performance (1999)
Table 6.3: Novel agents in late stage clinical development
Table 6.4: Combined financial data - pro forma data
Glaxo Wellcome (Uk)
Table 7.1: Business segment analysis (year end 31 December)
Table 7.2: Geographical sales analysis
Table 7.3: Therapy area sales analysis
Table 7.4: Human pharmaceuticals - major product performance (1999)
Table 7.5: Major commercial agreements
The Billion Dollar Pharmaceutical Club
Table 7.6: Novel agents in late stage clinical development
Table 7.7: Financial data
Smithkline Beecham Plc (Uk)
Table 8.1: Business segment analysis (year end 31 December)
Table 8.2: Therapy area sales analysis
Table 8.3: Human pharmaceuticals - major product performance (1999)
Table 8.4: Major commercial agreements
Table 8.5: Novel agents in late stage clinical development
Table 8.6: Financial data
Novartis Ag (Switzerland)
Table 9.1: Business segment analysis (year end 31 December)
Table 9.2: Geographical sales analysis
Table 9.3: Human pharmaceuticals - major product performance (1999)
Table 9.4: Major commercial agreements
Table 9.5: Novel agents in late stage clinical development
Table 9.6: Financial data
Roche Group (Switzerland)
Table 10.1: Business segment analysis (year end 31 December)
Table 10.2: Geographical sales analysis
Table 10.3: Therapy area sales analysis
Table 10.4: Human pharmaceuticals - major product performance (1999)
Table 10.5: Major commercial agreements
Table 10.6: Novel agents in late stage clinical development
Table 10.7: Financial data
Sanofi-Synthélabo (France)
Table 11.1: Business segment analysis (year end 31 December - pro forma data)
Table 11.2: Geographical sales analysis (pharmaceuticals)
Table 11.3: Therapy area sales analysis
Table 11.4: Human pharmaceuticals - major product performance (1999)
Table 11.5: Major commercial agreements
Table 11.6: Novel agents in late stage clinical development
Table 11.7: Financial data (year end 31 December)
Schering Ag (Germany)
Table 12.1: Business segment analysis (year end 31 December)
Table 12.2: Geographical sales analysis
Table 12.3: Therapy area sales analysis
Table 12.4: Human pharmaceuticals - major product performance (1999)
Table 12.5: Major commercial agreements
Table 12.6: Novel agents in late stage clinical development
Table 12.7: Financial data
|
TABLE OF CONTENTS
